skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Allergan PLC CEO Brent Saunders warned pharmaceutical manufacturers not to let the election of Donald Trump as president of the US to result in a false sense of security across the industry when it comes to the public controversy over high drug prices.


“I worry today that the pharma industry has a very false sense of relief or security because of a Trump administration and Republican-controlled Congress,” Saunders said, speaking during a panel on drug pricing during the Forbes Healthcare Summit in New York City Dec. 1.


Trump won the election on a populist campaign and the drug pricing issue is a populist issue, he reminded industry. Debate over the cost of pharmaceuticals is not likely to abate because many Americans are “rightfully angry,” Saunders said.


“To think President Trump isn’t a populist, that he won’t jump on the next Epipen scandal and tweet more on a pricing scandal than Hillary Clinton tweeted or anybody else…you are fooling yourself,” he said.


What the drug industry does appear to have won is a short reprieve to address drug pricing without government intervention, Saunders added.


“We have a little bit of time to solve it ourselves, but we don’t have a lot of time,” he said. “The next big scandal will revive the debate.”

 

Find more content for Scrip here.

 



Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: